Published in Cancer Weekly, December 12th, 2006
KOS-1584 is being evaluated in two phase I trials using different dosing regimens with the goal of defining the recommended phase II dose and to assess safety, pharmacokinetics, pharmacodynamics, and early evidence of antitumor activity. Data on KOS-1584 were presented in posters at the 18th American Association for Cancer Research (AACR)-U.S. National Cancer Institute (NCI)-European Organization for Research and Treatment of Cancer (EORTC) Symposium on "Molecular Targets and Cancer Therapeutics," in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.